Evidence map›Paper›PMID 41245588›Full record

ArticleCancer management and research2025

Rare Giant Pure Yolk Sac Tumor Originating from Cryptorchidism in an Adult.

Hengjiang Wu, Yu Zhang, Wei Zheng, Huayu Bao, Yuandi Fu, Qijian Su

Abstract readCase Reports
In one paragraph

Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hengjiang Wu *Department of Urology, The First People's Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People's Republic of China.
Yu Zhang *Department of Scientific Research, The First People's Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People's Republic of China.
Wei ZhengDepartment of Urology, The First People's Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People's Republic of China.
Huayu BaoDepartment of Urology, The First People's Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People's Republic of China.
Yuandi FuDepartment of Urology, The First People's Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People's Republic of China.
Qijian SuDepartment of Scientific Research, The First People's Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptorchidism is a well-established risk factor for testicular cancer. Among adult male patients, pure testicular yolk sac tumors (YSTs) are rare, and those arising from cryptorchidism in adult males are even less common. We report a case of a 35-year-old male with a giant YST originating from cryptorchidism, with no distant metastasis detected preoperatively. The initial treatment plan was radical orchiectomy combined with postoperative chemotherapy for curative intent, but direct surgery was extremely challenging due to the large tumor size. Therefore, we attempted neoadjuvant chemotherapy to facilitate surgical resection. To our knowledge, there are relatively few reports on the use of neoadjuvant chemotherapy to reduce tumor burden prior to testicular tumor resection. The patient received four cycles of neoadjuvant chemotherapy before surgery, after which the tumor volume decreased, and the levels of alpha-fetoprotein (AFP) and lactate dehydrogenase (LDH) also dropped. Unfortunately, Liver metastases were detected during the reexamination on the 28th post-operative day, and lung metastases were identified in another reexamination on the 85th post-operative day. Regrettably, the patient refused further treatment and discontinued it, and we eventually lost follow-up. Post-pubertal YSTs are highly aggressive, and early detection and intervention are crucial for patients suspected of having cryptorchidism. Neoadjuvant chemotherapy can be considered as an adjuvant therapeutic strategy for reducing tumor burden in testicular tumors.

Indexed as

cryptorchidismneoadjuvant chemotherapytesticular canceryolk sac tumor

Identifiers

PMID41245588
PMCPMC12619593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.